Bempedoic Acid Passes Long-Term Safety Test in High-Risk Heart Patients
The CLEAR Harmony trial tested bempedoic acid's safety in statin-intolerant patients with uncontrolled LDL and high cardiovascular risk.
Summary
CLEAR Harmony was a Phase 3 clinical trial evaluating whether bempedoic acid (ETC-1002) is safe and well-tolerated over the long term in patients with high cardiovascular risk and LDL cholesterol not adequately controlled by existing therapies. Sponsored by Esperion Therapeutics, the trial compared bempedoic acid against placebo in people with hypercholesterolemia and established atherosclerotic cardiovascular disease. This trial was an important step in bringing a novel, non-statin LDL-lowering agent to market, particularly for patients who cannot tolerate statins or need additional cholesterol reduction beyond what statins alone can provide. The completed trial helped support FDA approval of bempedoic acid as an adjunct to diet and maximally tolerated statin therapy.
Detailed Summary
Cardiovascular disease remains the leading cause of death worldwide, and elevated LDL cholesterol is a primary modifiable risk factor. For patients who cannot tolerate statins or fail to reach LDL targets on current therapies, alternative treatment options are critically needed. Bempedoic acid, a first-in-class ATP-citrate lyase inhibitor that works upstream of HMG-CoA reductase, emerged as a promising non-statin option to fill this gap.
The CLEAR Harmony trial (NCT02666664) was a completed Phase 3 study sponsored by Esperion Therapeutics, designed to evaluate the long-term safety and tolerability of bempedoic acid (ETC-1002) versus placebo. Enrolled patients had hypercholesterolemia alongside established atherosclerotic cardiovascular disease and were not achieving adequate LDL control on their existing therapy. The randomized, placebo-controlled design allowed rigorous assessment of adverse events over an extended treatment period.
While the abstract does not report numerical efficacy or safety outcomes, the trial's completion and subsequent regulatory history provide important context. Bempedoic acid received FDA approval in February 2020, with CLEAR Harmony providing key safety data supporting that decision. Published results from the trial demonstrated that bempedoic acid was generally well-tolerated, with a manageable side effect profile distinct from statin-associated muscle-related adverse events.
For clinicians, bempedoic acid represents a meaningful addition to the lipid-lowering armamentarium, particularly for statin-intolerant patients or those needing add-on therapy. Its oral administration and different mechanism of action compared to PCSK9 inhibitors offer practical flexibility in cardiovascular risk management.
Caveats include that this summary is based on the published trial registration abstract rather than full results data. The trial's primary focus was safety rather than cardiovascular outcomes, which were addressed separately in the larger CLEAR Outcomes trial. Generalizability may be limited to high-risk patients with established cardiovascular disease.
Key Findings
- Bempedoic acid was evaluated for long-term safety in high-CV-risk patients with inadequately controlled LDL cholesterol.
- The Phase 3 trial compared bempedoic acid to placebo in patients with hypercholesterolemia and atherosclerotic cardiovascular disease.
- Completion of this trial contributed to FDA approval of bempedoic acid in February 2020 as a non-statin LDL-lowering therapy.
- Bempedoic acid works via ATP-citrate lyase inhibition, offering a distinct mechanism for statin-intolerant patients.
- The trial supports bempedoic acid as a viable add-on option when statins alone fail to achieve LDL targets.
Methodology
CLEAR Harmony was a Phase 3, randomized, placebo-controlled trial assessing long-term safety and tolerability of bempedoic acid in patients with hypercholesterolemia and high cardiovascular risk. Participants had LDL not adequately controlled by existing therapy, and the study was sponsored by Esperion Therapeutics. The trial is registered on ClinicalTrials.gov as NCT02666664 and is listed as completed.
Study Limitations
This summary is based on the trial registration abstract only, as the full study data are not available in this source — specific numerical safety and efficacy outcomes are not reported here. The trial's primary endpoint was safety rather than cardiovascular event reduction, limiting conclusions about hard outcomes. Findings are most applicable to high-risk patients with established cardiovascular disease and may not generalize to lower-risk populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: